Abstract
Combination pharmaceutical products, or fixed-dose combinations (FDC' s), offer
benefits to many drug classes due to the additive nature of therapeutic effect
and the reduced level of side-effects associated with their use. Their core
advantage however is an improvement in convenience that stems from reducing
prescription numbers and their associated administrative costs. Although
fixed-dose combination drugs have historically attracted disapproval from
physicians, who typically prefer to determine the components and ratios of
drug applications at their own discretion, a widespread acknowledgement and
acceptance of these therapies has now been established. This is largely due to
their effectiveness in areas such as HIV and asthma, but the successful
positioning of combination products remains difficult in therapeutic areas
where combination therapies only provide marginally incremental benefits.
Launching Combination Products is a new report published by Business Insights
that provides detailed strategic guidance for the preparation and successful
execution of combination product launches. This report performs a
comprehensive examination of current competitive pressures, best practices and
future developments in key therapeutic areas including cardiovascular,
respiratory, HIV and women' s health. Detailed case studies also provide unique
insights into the brand extension and franchise development strategies of
leading companies and help to identify the key success factors behind recent
combination product launches. Discover potential growth opportunities for your
brands, identify future combination launches and use case studies to
understand the most effective launch strategies across key therapeutic areas
with this new report.
Table of Contents
Executive Summary
- An introduction to combination products
- Combination product strategies in the cardiovascular market
- Combination product strategies in the respiratory market
- Combination product strategies in the diabetes market
- Combination product strategies in the HIV market
- Combination product strategies in the women' s health market
- Combination product strategies in other therapeutic markets
- Brand extension and franchise development strategies
Chapter 1 An introduction to combination products
- Summary
- Introduction
- Therapeutic value
- Combining therapies
- Improved convenience
- Commercial value
- Brand extension
- Franchise development
- Leading combination products
- Key products
- Key therapeutic categories
- Key combination product strategies
Chapter 2 Strategies for cardiovascular products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Exforge
- Future combination product developments
- Simcor
- Avandia/simvastatin
- Key combination product launch strategies
Chapter 3 Strategies for respiratory products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Symbicort
- Future combination product developments
- Singulair/Claritin
- Flutiform
- Key combination product launch strategies
Chapter 4 Strategies for diabetes products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Janumet
- Duetact
- Future combination product developments
- Avandia/simvastatin
- Synordia
- Key combination product launch strategies
Chapter 5 Strategies for HIV products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Atripla
- Future combination product developments
- Key combination product launch strategies
Chapter 6 Strategies for women' s health
- products
- Summary
- Introduction
- Leading combination products
- Recent combination product launches
- Lybrel
- Angeliq
- Future combination product developments
- Aprela
- DUB-OC
- Key combination product launch strategies
Chapter 7 Strategies for other therapeutic areas
- Summary
- Introduction
- Leading combination products
- Anti-infectives
- Recent combination product launches
- Combigan
- Ziana
- Pylera
- Future combination product developments
- Oncology
- CNS and pain
- Key combination product launch strategies
Chapter 8 Brand extension and franchise development strategies
- Summary
- Introduction
- Case studies
- Diovan, Diovan HCT/Co-Diovan and Exforge
- Avandia, Avandamet and Avandaryl
- Advair/Seretide
- Case study: Kaletra
- Case study: Vytorin
- Key success factors
- Branding
- Pricing
- Positioning
Chapter 9 Appendix
- Sources
- Product sales data
- Regulatory data
- Specific sources
List of Figures
- Figure 1.1: Number of combination products by therapy area, 2006
- Figure 1.2: Key combination product strategies
- Figure 2.3: Key cardiovascular combination product strategies
- Figure 3.4: Key respiratory combination product strategies
- Figure 4.5: Key diabetes combination product strategies
- Figure 6.6: Key women' s health combination product strategies
- Figure 8.7: Diovan, Diovan HCT/Co-Diovan sales, 2002-2006
- Figure 8.8: Avandia, Avandamet and Avandaryl sales, 2002-2006
- Figure 8.9: Advair/Seretide, Flovent/Flixotide and Serevent sales,
2002-2006
- Figure 8.10: Kaletra sales, 2002-2006
- Figure 8.11: Vytorin, Zetia and Zocor sales, 2002-2006
List of Tables
- Table 1.1: Leading brand extension combination products, 2006
- Table 1.2: Leading brand extension combination products, 2006
- Table 1.3: Leading franchise development combination products, 2006
- Table 2.4: Leading brand extension combination products in the
cardiovascular market, 2004-2006
- Table 2.5: Leading franchise development combination products in the
cardiovascular market, 2004-2006
- Table 2.6: Recently approved combination products in the cardiovascular
market, 2005-2007
- Table 2.7: Future combination products in development for the
cardiovascular market, 2007
- Table 3.8: Leading brand extension combination products in the respiratory
market, 2004-2006
- Table 3.9: Leading franchise development combination products in the
respiratory market, 2004-2006
- Table 3.10: Recently approved combination products in the respiratory
market, 2005-2007
- Table 3.11: Future combination products in development for the respiratory
market, 2007
- Table 4.12: Leading brand extension combination products in the diabetes
market, 2004-2006
- Table 4.13: Recently approved combination products in the diabetes market,
2005-2007
- Table 4.14: Future combination products in development for the diabetes
market, 2007
- Table 5.15: Leading franchise development combination products in the HIV
market, 2004-200660
- Table 5.16: Recently approved combination products in the HIV market,
2005-2007
- Table 6.17: Leading brand extension combination products in the women' s
health market, 2004-2006
- Table 6.18: Leading franchise development combination products in the
women' s health market, 2004-2006
- Table 6.19: Recently approved combination products in the women' s health
market, 2005-2007
- Table 6.20: Future combination products in development for the women' s
health market, 2007
- Table 7.21: Leading brand extension combination products in other
therapeutic markets, 2004-2006
- Table 7.22: Leading franchise development combination products in other
therapeutic markets, 2004-2006
- Table 7.23: Recently approved combination products in other therapeutic
markets, 2005-2007
- Table 7.24: Future combination products in development for other
therapeutic markets, 2007
|
